Aclarion's Nociscan AI Technology Gains Traction in Chronic Low Back Pain Diagnosis

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnosis, has reported significant progress in establishing its Nociscan AI technology as a standard of care decision support tool. The company's recent achievements include securing coverage from three of the four largest private insurance payers in the UK, partnering with key opinion leaders (KOLs) in spine surgery, and advancing clinical studies to support wider adoption.

The company's strategy focuses on partnering with KOL physicians who advocate for insurance coverage of Nociscan. This approach has led to success in the UK, where physicians' evaluation of the technology resulted in a commercial agreement with The London Clinic and subsequent coverage decisions by major private health insurance providers. Aclarion is now replicating this model in the United States through its panel of 10 prominent spine surgeon leaders.

In addition to its KOL strategy, Aclarion has entered into a strategic partnership with ATEC, a spine implant company, to expand access to more physicians. The company has also executed commercial agreements in key U.S. markets and is exploring opportunities in the personal injury and workers' compensation sectors.

Clinical evidence supporting Nociscan's efficacy continues to grow. The company has published peer-reviewed articles demonstrating improved patient outcomes when Nociscan results guide surgical treatment. An economic analysis commissioned by Aclarion suggests that widespread use of Nociscan could save the U.S. healthcare system nearly half a billion dollars annually.

Aclarion's flagship clinical study, CLARITY, is currently underway to compare outcomes of patients undergoing surgery for chronic discogenic back pain with and without Nociscan in the decision-making process. The company anticipates that positive results from this study could lead to broader insurance coverage and endorsements from major spine societies.

As Aclarion continues to expand its intellectual property portfolio and gather clinical evidence, the company expects to announce additional peer-reviewed publications, commercial agreements, and payer coverage decisions in the coming months. These developments position Nociscan as a potentially disruptive technology in the diagnosis and treatment of chronic low back pain, which is estimated to cost Americans $134 billion annually.